GSK plc (GSK)
After hours:
| Previous close | 35.27 |
| Open | 35.47 |
| Bid | 35.58 x 1800 |
| Ask | 35.70 x 2900 |
| Day's range | 35.39 - 35.74 |
| 52-week range | 28.47 - 46.97 |
| Volume | |
| Avg. volume | 3,662,933 |
| Market cap | 72.837B |
| Beta (5Y monthly) | 0.27 |
| PE ratio (TTM) | 12.35 |
| EPS (TTM) | 2.88 |
| Earnings date | 01 Feb 2017 - 06 Feb 2017 |
| Forward dividend & yield | 1.48 (4.07%) |
| Ex-dividend date | 23 Feb 2023 |
| 1y target est | 44.11 |
- GlobeNewswire
GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection
Brexafemme complements GSK’s industry-leading infectious disease portfolio with an FDA approved treatment for vulvovaginal candidiasisSCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royaltiesSCYNEXIS retains rights to all other assets derived from enfumafungin, with GSK having a right of first negotiation to these pre-clinical and discovery stage assetsSCYNEXIS to host an investor call and webcast at 8:30 a.m. EDT today LONDON a
- Motley Fool
Better RSV Vaccine Stock: Pfizer, GSK, or Moderna?
No vaccine has been approved to prevent respiratory syncytial virus (RSV), but there are more than 30 different RSV vaccine candidates in clinical trials, according to PATH, a global health organization. Research from the Centers for Disease Control and Prevention (CDC) estimate that between 60,000 and 160,000 adults 65 and older are hospitalized each year with RSV, and 6,000 to 10,000 older adults die because of it. One to two out of every 100 children younger than 6 months of age with an RSV infection may need to be hospitalized.
- Business Wire
GSK and Earvin "Magic" Johnson Partner to Raise Awareness of Risk of RSV in Older Adults
PHILADELPHIA, March 14, 2023--GSK and Earvin "Magic" Johnson Partner to Raise Awareness of Risk of RSV in Older Adults
